NeoRx Verluma lung cancer imaging agent to be introduced in fourth quarter by DuPont Merck.
This article was originally published in The Gray Sheet
Executive Summary
NEORx VERLUMA LUNG CANCER IMAGING AGENT LAUNCH BY DUPONT MERCK slated for the fourth quarter, DuPont Merck says. FDA approved a product license application on Aug. 20 for the technetium Tc 99 monoclonal antibody agent for detecting small-cell lung cancer.